Stockreport

Xencor Signs Four Commercial License Agreements with Selexis SA to Advance its Pipeline of XmAb Bispecific Antibody Drug Candidates

Xencor, Inc.  (XNCR) 
Last xencor, inc. earnings: 2/24 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.xencor.com/investor-relations
PDF Expanded Partnership Leverages Selexis’ Expertise in Recombinant Therapeutic Development Solutions GENEVA--(BUSINESS WIRE)-- Selexis SA, [Read more]